Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
Primary Care
How do you approach treatment intensification in patients with RA and low disease activity but not in remission, considering the potential risks of increased immunosuppression?
Related Questions
What is your approach to monitoring patients referred for high titer +RF and +CCP but without active symptoms of inflammatory arthritis?
What is your treatment approach for a young female who has an idiopathic small right elbow effusion with synovial thickening that has resulted in limitation in her range of motion?
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
What is your approach to diagnosing and managing methotrexate-induced alopecia?
How do you help patients understand the difference between prolonged morning stiffness and pain?
Would you ever consider retreatment with an antiresorptive medication in a patient with a remote history of atypical fracture attributed to an oral bisphosphonate?
Is there any role for administering another course of recombinant zoster vaccine (Shingrix) in a previously vaccinated patient with RA, who is in clinical remission on JAK inhibitor but has had a breakthrough shingles infection?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
